Shanghai Runshi Pharmaceutical Technology Co., Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-32
RECRUITING0
READOUTS ≤12 MONTHS4
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| DP303c NCT06577376 |
P1/2 | Not yet recruiting | Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma; Expressing Human Epidermal Growth Factor Receptor-2 (HER-2) | 252 | 2026-08-26 |
| SYHA1813 NCT06682611 |
P1/2 | Not yet recruiting | Unresectable Locally Advanced or Metastatic Solid Tumors | 380 | 2026-11-13 |
| simmitinib NCT06656091 |
P3 | Not yet recruiting | Advanced Oesophageal Squamous Cell Carcinoma | 450 | 2027-01-30 |
| Simmitinib NCT06132217 |
P1/2 | Not yet recruiting | Advanced Solid Tumor | 168 | 2027-01-30 |
| SYHA1813 NCT06739213 |
P2 | Not yet recruiting | Recurrent or Progressive High Grade Meningioma | 56 | 2027-01-31 |
| SYHA1813 NCT07613450 |
P3 | Not yet recruiting | High Grade Meningioma | 136 | 2029-07-31 |